How much theophylline is enough?

Fairshter, Ronald D.

doi:10.1016/0002-9343(88)90243-4

Cited by 9 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observation is not sur prising since, as shown here and in other studies [14,17], bronchodilatation from theophylline is related to the logarithm of the plasma level. Such a relationship would predict substantial functional im provement at lower theophylline concen trations with continued (but proportion ately lesser bronchodilatation at higher theophylline levels [18].…”

Section: Discussionmentioning

confidence: 99%

Comparison of Once-a-Day and Twice-a-Day Theophylline in Asthma

Fairshter¹,

Lowe²,

Wilson³

et al. 1986

Respiration

View full text Add to dashboard Cite

Sustained-release theophylline compounds given once (Uniphyl) or twice (Theodur) daily were compared in adult asthmatics. Following a single dose of oral medication, large and peripheral airways bronchodilation occurred; response to theophylline correlated significantly with the log plasma theophylline concentration. Cardiac output and stroke volume, measured noninvasively using the acetylene technique, also increased significantly. During maintenance therapy, both preparations caused similar improvements in pulmonary function and symptoms; however, side effects were less with once-daily therapy

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Once-a-Day and Twice-a-Day Theophylline in Asthma

Fairshter¹,

Lowe²,

Wilson³

et al. 1986

Respiration

View full text Add to dashboard Cite

show abstract

“…The difficulty in obtaining a serum theophylline level >10 µg·mL -1 in the long-term treatment of reversible airway obstruction is well-known, because of the difficulties in using this drug [14]. However, the therapeutic benefit of theophylline in treating airways obstruction is dose-related, and can be observed at levels as low as 5 µg·mL -1 , particularly when theophylline is given in conjunction with β 2 -agonists [15,16]. In our study, only nine subjects in the theophylline group showed a serum theophylline concentration <5 µg·mL -1 at the end of the active treatment, suggesting that compliance with the treatment was acceptable.…”

Section: Discussionmentioning

confidence: 99%

Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group

Paggiaro¹,

Giannini²,

Franco³

et al. 1996

Eur Respir J

View full text Add to dashboard Cite

The median percentage of nights with no asthma symptoms rose from 14% in both groups at baseline to 71% with salmeterol and to 46% with theophylline (p=0.044). There was also a significant increase for salmeterol in the median percentage of nights with no rescue salbutamol use (from 36 to 86%) compared with theophylline (from 71 to 78%; p=0.002). The mean morning PEF increased from 337 L·min -1 in the salmeterol group and 332 L·min -1 in the theophylline group to 372 and 357 L·min -1 , respectively. No significant difference between the two treatments was observed for PEF, symptoms or additional salbutamol medication during the day. The incidence of gastrointestinal symptoms (gastric irritation, nausea and vomiting) was greater among patients receiving theophylline (11%) than with salmeterol (3%).These findings suggest that inhaled salmeterol is more effective in relieving symptoms of asthma, and better tolerated than theophylline in patients with moderateto-severe asthma. Eur Respir J., 1996Respir J., , 9, 1689Respir J., -1695 The clinical efficacy of salmeterol, the first of a new class of long-acting β 2 -agonists, has been demonstrated in comparison with other short-acting β 2 -agonists, such as salbutamol and terbutaline [1,2]. As oral theophylline is an asthma drug widely used in many countries, especially in Europe, this study was planned to compare the effects of salmeterol with oral slow-release theophylline. The new slow-release preparations of oral theophylline allow quite stable levels of serum theophylline concentration with one or two daily administrations, and they are commonly accepted for treatment of chronic reversible airway obstruction [3]. In this respect, the comparison between oral slow-release theophylline and salmeterol, both drugs with a long-lasting (up to 12 h) bronchodilation achieved by twice daily administration, seems of particular interest for long-term treatment of reversible airway obstruction. In a previous study, the effect of salmeterol was compared with theophylline over 2 weeks in a double-blind, cross-over study [4], showing that salmeterol produced a better effect on asthma symptoms and peak expiratory flow (PEF) values than theophylline in subjects with moderate asthma. Salmeterol was also shown to be more effective than a combination of slow-release theophylline and ketotifen in producing disappearance of nocturnal symptoms, lung function and rescue salbutamol use, during a 2 week period of treatment in 115 patients with nocturnal asthma [5].This large multicentre study was conducted in 24 European Centres, in order to compare the efficacy and tolerability of salmeterol with oral theophylline in the treatment of moderate-to-severe asthma. Subjects and methods SubjectsTwo hundred and forty three patients with moderateto-severe asthma were recruited into the study. Inclusion criteria were: 1) male or female aged 18-70 yrs; 2) symptoms of asthma (dyspnoea, wheeze, cough) for at least 1 year; 3) reversible airway obstruction (forced expiratory volume in one second (FEV1)...

show abstract

Reassessing the Therapeutic Range for Theophylline on Laboratory Report Forms: Another Viewpoint

Jenne

1993

Pharmacotherapy

View full text Add to dashboard Cite

How much theophylline is enough?

Cited by 9 publications

References 43 publications

Comparison of Once-a-Day and Twice-a-Day Theophylline in Asthma

Comparison of Once-a-Day and Twice-a-Day Theophylline in Asthma

Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group

Reassessing the Therapeutic Range for Theophylline on Laboratory Report Forms: Another Viewpoint

Contact Info

Product

Resources

About